Comparative Pharmacology
Head-to-head clinical analysis: ARZERRA versus ZIRABEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARZERRA versus ZIRABEV.
ARZERRA vs ZIRABEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
ZIRABEV (bevacizumab-awwb) is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A and prevents its interaction with VEGFR-1 and VEGFR-2 receptors on endothelial cells, thereby inhibiting angiogenesis.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
15 mg/kg intravenously over 60 minutes on Day 1 of each 3-week cycle
None Documented
None Documented
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Terminal elimination half-life is approximately 20 days (range 11-50 days). This long half-life supports extended dosing intervals (e.g., every 2-3 weeks).
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
ZIRABEV (bevacizumab) is eliminated primarily via metabolic degradation in the reticuloendothelial system. Renal excretion is minimal (<1% as unchanged drug in urine). Biliary/fecal excretion accounts for the remainder of metabolites.
Category C
Category C
Antineoplastic, Monoclonal Antibody
Monoclonal Antibody